THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL (TOGETHER THE "RESTRICTED JURISDICTIONS" AND EACH BEING A "RESTRICTED JURISDICTION"). PLEASE SEE THE IMPORTANT NOTICE IN APPENDIX II TO THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN GENINCODE PLC OR ANY OTHER ENTITY IN ANY JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF GENINCODE PLC.

THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, YOU SHOULD READ AND UNDERSTAND THE INFORMATION PROVIDED IN APPENDIX II WHICH CONTAINS THE TERMS AND CONDITIONS OF THE PLACING.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY MAR. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

21 January 2026                                       

GENINCODE PLC

("GENinCode" or the "Company")

Placing and Subscription to raise a minimum of £3.5 million

Retail Offer to raise up to £0.5 million

at a price of 1 pence per share

and

Notice of General Meeting

GENinCode plc (AIM: GENI.L), the genetics company focused on the prevention of cardiovascular disease ("CVD") and the early detection of ovarian cancer, today announces its intention to raise a minimum of £3.5 million through a placing (the "Placing") to new and existing institutional investors ("Placees") and a subscription, both at the issue price of 1 pence per share ("Issue Price").

The Placing will be conducted by way of an accelerated bookbuild ("ABB") which will be launched immediately following this announcement in accordance with the terms and conditions set out in Appendix II to this Announcement. The final number of Placing Shares to be placed at the Issue Price will be determined at the close of the ABB.

The Placing is being undertaken by Cavendish Capital Markets Limited ("Cavendish"), Oberon Capital, a trading name of Oberon Investments Limited, ("Oberon") and Turner Pope Investments (TPI) Ltd ("Turner Pope") as Joint Bookrunners to the Placing.

The Company proposes to raise £0.9 million (before expenses) by way of a proposed subscription, comprising the issue of 87,300,000 new Ordinary Shares ("Subscription Shares") at the Issue Price (the "Subscription") to Nestor Oller and certain Directors.

In addition, the Company intends to carry out a separate retail offer of up to 50,000,000  new Ordinary Shares ("Retail Offer Shares" and together with the Placing Shares and the Subscription Shares, the "New Ordinary Shares") at the Issue Price to raise further gross proceeds of up to £0.5 million via the WRAP platform (the "Retail Offer" and together with the Placing and the Subscription, the "Fundraising") to provide existing retail shareholders in the United Kingdom with an opportunity to participate in the Fundraising. A separate announcement will be made shortly regarding the Retail Offer and its terms. Completion of the Retail Offer is conditional, inter alia, upon completion of the Placing and Subscription but completion of the Placing and Subscription are not conditional upon the Retail Offer. For the avoidance of doubt the Retail Offer forms no part of the Placing or Subscription.

Transaction Highlights:

·      GENinCode is conducting a conditional Placing and Subscription to raise a minimum of £3.5 million (before expenses) through the proposed issue of New Ordinary Shares.

·      The Placing is expected to raise a minimum of £2.6 million through the issue of Placing Shares.

·      Certain entities associated with existing shareholder, Nestor Oller, and certain Directors of the Company intend to enter into the Subscription and will conditionally subscribe for 87,300,000 Subscription Shares raising £0.9 million in aggregate.

·      The Issue Price of 1 pence represents a discount of 47.4 per cent. to the closing middle market price of 1.90 pence per Ordinary Shares on 20 January 2026, being the last business day prior to the announcement of the Fundraising.

·    The gross proceeds of the Fundraising, which are expected to amount to a minimum of £3.5 million (and up to a further £0.5 million assuming full take up of the Retail Offer), will be used to fund its US commercialisation and scale-up program, its EU and UK expansion program and the costs of the Fundraising and general working capital.

·      Completion of the Fundraising is conditional, inter alia, upon approval of the shareholder resolutions (at the general meeting of the Shareholders to be held on 9 February 2026 (the "General Meeting").

·      The final number and allocation of the Placing Shares will be determined by Cavendish, Oberon and Turner Pope in agreement with the Company and the result of the Placing will be announced as soon as practicable after the release of this announcement and completion of the ABB.

A circular, containing further details of the Fundraising and the notice of the General Meeting to be held at 11.00 a.m. on 9 February 2026 to, inter alia, approve the resolutions required to implement the Fundraising, is expected to be published and despatched to Shareholders on or around 22 January 2026 (the "Circular"). Set out below in Appendix I is an adapted extract from the draft Circular that is proposed to be sent to Shareholders after the closure of the ABB. Following its publication, the Circular will be available on the Group's website at https://investors.genincode.com/.

For further information contact:

Notes:

References to times in this Announcement are to London time unless otherwise stated.

The times and dates set out in the expected timetable of principal events above and mentioned throughout this Announcement may be adjusted by the Company in which event the Company will make an appropriate announcement to a Regulatory Information Service giving details of any revised dates and the details of the new times and dates will be notified to London Stock Exchange plc (the "London Stock Exchange") and, where appropriate, Shareholders. Shareholders may not receive any further written communication.

Further information on the Fundraising and Admission is included in Appendix I below. Attention is also drawn to the section headed 'Important Information' of this Announcement and the terms and conditions of the Placing (representing important information for Placees only) in Appendix II to this Announcement.

IMPORTANT INFORMATION

This Announcement has been issued by, and is the sole responsibility, of the Company. 

Cavendish Capital Markets Limited ("Cavendish"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting as nominated adviser, lead broker and joint bookrunner to the Company in connection with the Placing. The responsibilities of Cavendish as the Company's Nominated Adviser under the AIM Rules for Companies and the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company or to any director or shareholder of the Company or any other person. Cavendish will not be responsible to any person other than the Company for providing the protections afforded to clients of Cavendish or for providing advice to any other person in connection with the Placing or any acquisition of shares in the Company.

Oberon Capital, a trading name of Oberon Investments Limited, ("Oberon"), which is authorised and regulated by the FCA in the United Kingdom and is acting as joint bookrunner to the Company and no one else in connection with the Placing, and Oberon will not be responsible to anyone (including any purchasers of the Placing Shares) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

Turner Pope Investments (TPI) Ltd ("Turner Pope"), which is authorised and regulated by the FCA in the United Kingdom and is acting as joint bookrunner to the Company and no one else in connection with the Placing, and Turner Pope will not be responsible to anyone (including any purchasers of the Placing Shares) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

Cavendish, Oberon and Turner Pope (the "Joint Bookrunners") are not making any representation or warranty, express or implied, as to the contents of this Announcement. The Joint Bookrunners have not authorised the contents of, or any part of, this Announcement, and no liability whatsoever is accepted by the Joint Bookrunners for the accuracy of any information or opinions contained in this Announcement or for the omission of any material information. Neither the Company, the Joint Bookrunners nor any of their respective parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisers, or any other person their respective affiliates and advisers, agents and/or any other party undertakes or is under any duty to update this announcement or to correct any inaccuracies in any such information which may become apparent or to provide any person with any additional information. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, this announcement. In addition, no duty of care or otherwise is owed by any such person to recipients of this announcement or any other person in relation to this announcement.

This Announcement does not constitute, or form part of, a prospectus relating to the Company, nor does it constitute or contain any invitation or offer to any person, or any public offer, to subscribe for, purchase or otherwise acquire any shares in the Company or advise persons to do so in any jurisdiction, nor shall it, or any part of it form the basis of or be relied on in connection with any contract or as an inducement to enter into any contract or commitment with the Company. In particular, the New Ordinary Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended or qualified for sale under the laws of any state of the United States or under the applicable laws of any of Canada, Australia, Japan, or the Republic of South Africa, and may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as such term is defined in Regulation S under the Securities Act) or to any national, resident or citizen of Canada, Australia, Japan, or the Republic of South Africa.

The distribution or transmission of this Announcement and the offering of the New Ordinary Shares in certain jurisdictions other than the UK may be restricted or prohibited by law or regulation. Persons distributing this Announcement must satisfy themselves that it is lawful to do so. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken by the Company that would permit an offering of such shares or possession or distribution of this Announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company to inform themselves about, and to observe, such restrictions. In particular, this Announcement may not be distributed, directly or indirectly, in or into a Restricted Jurisdiction. Overseas Shareholders and any person (including, without limitation, nominees and trustees), who have a contractual or other legal obligation to forward this Announcement to a jurisdiction outside the UK should seek appropriate advice before taking any action.

This Announcement includes "forward-looking statements" which includes all statements other than statements of historical fact, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this Announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules for Companies.

No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

This announcement does not constitute a recommendation concerning any investor's option with respect to the Placing. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information.

The New Ordinary Shares will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange.

Appendix II to this Announcement (which forms part of this Announcement) sets out the terms and conditions of the Placing. By participating in the Placing, each person who is invited to and who chooses to participate in the Placing by making or accepting an oral and legally binding offer to acquire Placing Shares will be deemed to have read and understood this Announcement in its entirety (including the Appendix II) and to be making such offer on the terms and subject to the conditions set out in this Announcement and to be providing the representations, warranties, undertakings and acknowledgements contained in Appendix II.

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this Announcement.

The price and value of securities can go down as well as up. Past performance is not a guide to future performance.

Information to Distributors

UK Product Governance Requirements

Solely for the purposes of the Product Governance requirements contained within Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all distribution channels as are permitted by UK Product Governance Requirements (the "UK Target Market Assessment"). Notwithstanding the UK Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The UK Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the UK Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the UK Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A, respectively, of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to, the Placing Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

EU Product Governance Requirements

Solely for the purposes of the product governance requirements contained within (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"), (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II and (c) local implementing measures (together the "EU Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the EU Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by EU Product Governance Requirements (the "EU Target Market Assessment"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the EU Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

APPENDIX I - EXTRACT FROM THE CIRCULAR

Introduction

The Fundraising consists of the Placing, and the Subscription and the Retail Offer. The Fundraising is conditional on, inter alia, the Resolutions being passed by the Shareholders at the General Meeting and Admission becoming effective.

You will find at the end of the Circular a notice convening a general meeting to be held at Cavendish Capital Markets Limited, 1 Bartholomew Close, London EC1A 7BL on 9 February 2026 at 11:00 a.m. to consider and, if thought appropriate, pass the Resolutions which will permit the directors of the Company to issue and allot the New Ordinary Shares and to do so for cash, free of pre-emption rights.

Subject to Shareholder approval of the Resolutions at the General Meeting, application will be made for the New Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will become effective at 8.00 a.m. on 11 February 2026 (or such later date as the Company and the Joint Bookrunners may agree, but not later than 27 February 2026).

Subject to the Resolutions being passed by Shareholders at the General Meeting, each of the New Ordinary Shares will, on Admission rank pari passu in all respects with the Existing Ordinary Shares and will rank in full for all dividends and other distributions declared, made or paid on the New Ordinary Shares after Admission.

The Issue Price represents a discount of approximately 47.4 per cent. to the Closing Price of 1.9 pence per Existing Ordinary Share on 20 January 2026, being the latest practicable date prior to the announcement of the Fundraising.

The purpose of the Circular is to provide you with information about the background to and the reasons for the Fundraising, to explain why the Board considers the Fundraising to be in the best interests of the Company and its Shareholders as a whole and why the Directors recommend that you vote in favour of the Resolutions as they intend to do in respect of their respective shareholdings. A notice convening the General Meeting to approve the Resolutions is set out at the end of the Circular.

Importance of vote

If the Resolutions are not approved by Shareholders at the General Meeting, the Fundraising would not proceed as currently envisaged and, as such, the anticipated net proceeds of the Fundraising would not become available to the Company. There is no certainty that other funding would be available on suitable terms or within an appropriate time frame or at all. Accordingly, in light of the Group's low cash position, it would be likely that the Company would have insufficient capital to be able to continue trading.

Background to and reasons for the Fundraising

Background to GENinCode plc

GENinCode is a genetics company focussed on the prevention of cardiovascular disease ("CVD") and the early detection of ovarian cancer. Significant investment has been made in technology and product development to advance the Company's mission of improving patient outcomes through predictive and preventive care. The Company has recently announced it is working with its partner, Thermo Fisher Scentific, to support its revenue scale-up and expansion strategy for its lead product CARDIO inCode-Score across Europe, the UK, and the United States which will assist the Company to transitioning towards break-even over the medium term.

CVD is the leading cause of death worldwide, responsible for over 17.9 million deaths annually, which equates to approximately 31% of all global deaths (World Health Organisation). With the global annual cost of CVD projected to surpass $1.04 trillion by 2030, the directors believe there is an unmet need to accelerate the adoption of genetic testing as an adjunct to the current standard of care. The directors believe GENinCode's proprietary solutions address this unmet need by integrating genetic and clinical data to improve risk prediction, risk assessment, and personalised treatment pathways for CVD and related conditions.

Clinical Evidence Base and Early Commercialisation Approach

The Company developed the CARDIO inCode-Score genetic test (Polygenic Risk Score) following studies which identified genes and single nucleotide polymorphisms (SNPs) associated with the incidence of coronary heart disease (CHD).  A genotyping test (CARDIO inCode-Score) was then developed to identify the SNPs for clinical validation and commercialisation. The genes, SNPs and algorithms used to calculate the polygenic risk score have received granted patent status in the US and EU.

The CARDIO inCode-Score test has been clinically evaluated and validated over the past 10 years by Kaiser Permanente Division of Research and investigated in more than 63,000 adult individuals with no history of CHD who were part of the Northern California Genetic Epidemiology Resource in Adult Health and Aging (GERA) multi-ethnic cohort. The GERA cohort followed the individuals over an average of 14 years, using CARDIO inCode-Score to assess the polygenic risk of CHD and its clinical utility to assess the incidence of CHD.

The clinical data has allowed the Company to develop and commercialise the test for use in the US as a Laboratory Developed Test (LDT) in its CLIA certified lab in Irvine, California.  The Company announced in December 2025 that it had received test approval for CARDIO inCode-Score® by the New York State Department of Health, Clinical laboratory Evaluation Program. This approval required rigorous analytical and clinical test validation, extensive quality documentation and the completion of a comprehensive application and laboratory audits.

The approval of CARDIO inCode-Score® test by the New York State Department of Health now completes the full state coverage under US Centers for Medicare and Medicaid Services (CMS) as well as the ability to collect patient samples from New York State physicians, clinics, and health institutions for testing at its Irvine, California lab facility which has also received a New York State clinical test permit.

In order for the test to be marketed nationally across the US (i.e. sold to other third-party labs as a Medical Device or in a kit format) CARDIO inCode-Score requires FDA clearance.

FDA Engagement:

The Company was originally guided by the FDA that the CARDIO inCode-Score test could be approved as a 510k Medical Device using a predicate test which should have allowed for a relatively straight forward application and timeline.  The 510k application was filed in August 2023.

However, in November 2023 the FDA informed the Company that it had concluded, after further review, that it expected the test to be classified as 'De Novo' first in class application. While a De Novo is a more involved process, the Company understood that the extended timescale and additional submission requirements would not be extensive.

The Company has had good engagement with the FDA over this period and the De Novo Medical Device application completed its Substantive Review in July 2024.  The Substantive Review is an in-depth evaluation phase where the FDA thoroughly examines the medical device (or drug submission) to determine it is safe, effective and meets the regulatory standards. It typically involves detailed scientific assessment and communication with the Company to resolve any substantive issues before a final decision.

This gave the Company confidence to expect an approval in 2025 however in April 2025 the FDA provided full feedback on the application and determined that there remained certain outstanding elements, including some deficiencies mainly in relation to clinical validation that needed to be addressed.  As this did not reflect what the Company had expected given its previous communications and engagement with the FDA, it resulted in the Company initiating an FDA Supervisory Review including additional discussions with the FDA to understand the reasoning for the cited deficiencies. In July 2025, the FDA finalised the Supervisory Review and provided a formal response. Whilst the number of the outstanding deficiencies were reduced by the Supervisory Review, the review upheld the FDA's prior view that there remained further specific information required to address these deficiencies.

During the period since July 2025, the Company has worked with FDA to address and resolve these deficiencies with the list distilled into four areas:

·    Clinical validation - Ancestry/Ethical make-up of the original Northern California cohort

The FDA has requested further data on sub-group analysis of the African American population as the Kaiser Permanente Northern California (KPNC) cohort was not felt to be sufficiently powered for a relevant cross-section of the African American population. The African American population is generally not well represented in US healthcare plans due to socio-economic issues and there was a reduced number (2,084 patients) of African American ancestry in the California dataset of 63,000 patients.

Fortunately, the KPNC data set is a subset of a much larger Kaiser Permanente data set of c400,000 patient records (the KPRB dataset) capturing patient information from other US states where there is a greater representative population of African American patients (estimated at >10,000).  This data set has been constructed on a similar basis to the KPNC cohort i.e. with the relevant genetic information to be able to demonstrate the genetic risk and incidence of CHD. 

The Company has informed the FDA of the KPRB data set and is working with the FDA to ensure that data provided from the new data set will satisfy the FDA requirements. The Company will provide the analysis of this data as an update to its De Novo submission to resolve this outstanding deficiency. The new data set will also provide a more robust population data set.

Preparation for the study has started and is expected to take approximately 3 months to complete. The Company expects to provide more substantive data across all its population sub-groups, but especially the African American population.

·    Clinical validation - Medical Chart review of the records provided by Kaiser Permanente to confirm their accuracy of coronary event (case and non-case) classification

Kaiser Permanente is a well-respected US healthcare institution and leader in US healthcare standards of care, especially in Cardiology. It uses the internationally recognised ICD codes for clinically recording CHD events e.g. heart attack. These events appear on medical records if the patient has had a coronary event.  The ICD codes are widely used by US physicians and the FDA has requested a test sample of the 'cases' and 'non-cases' to be reviewed by Kaiser Permanente cardiologists to ensure they are correct.

The Company believes there is a very low possibility that there are errors in the Kaiser Permanente medical record event code classifications and has agreed with Kaiser to take 500 blinded medical record ICD code 'cases' and 'non-cases' and have two independent Kaiser cardiologists review the underlying medical notes to assess whether a cardiovascular event was correctly classified. the Directors expect that this can be completed over a few days once the above study is complete.

·    Analytical validation

The FDA requested additional CARDIO inCode-Score test information relating to the lab processes used and the measures required to ensure samples are appropriately acquired and results are consistent and accurate when using the test. The Company is preparing this data in line with its FDA discussions and believes the provision of this information will satisfy the FDA requirements.

·    Cybersecurity:

This is an area where the Company does not see a major impediment and it will provide Quality Assurance documentation to show its systems meet cybersecurity standards with these standards forming part of the Company's Quality Management System.

The Company is working closely with the FDA to confirm that the above deficiencies are satisfactorily resolved by the provision of the above data and information.  This is expected to be submitted at the end of Q1 2026 which would allow for an expected response around the end of Q2 2026.  FDA may not give this confirmation given its nature as a regulator who reserves their right to ask additional questions, but the Board feels confident that this should be the case.

In December 2025, the Company announced it had received New York State clinical test approval of CARDIO inCode-score®, enabling commercial promotion of the test in the state and a New York State permit for testing in its Irvine, California lab.

US Reimbursement

In January 2025, the Company announced that its CARDIO inCode test had been included in the U.S. Centres for Medicare and Medicaid Services (CMS) 2025 Clinical Lab Fee Schedule with a median price of approximately $500 per test. This development is an important step in facilitating reimbursement from Medicare and Medicaid across the United States. In addition, the Company is preparing a MolDx submission for US state-based reimbursement following receipt of FDA approval.

LIPID inCode has an average reimbursement of $1,229, reflecting the Clinical Laboratory Fee Schedule for the test and the broad Familial Hypercholesterolemia Panel of tests to identify FH genetic variants.

Commercial Collaborations

Thermo Fisher Scientific

In December 20205, GENinCode and Thermo Fisher Scientific signed a collaboration covering manufacturing, distribution and sales of CARDIO inCode-Score to laboratories across the US and Europe, Middle East and Africa (EMEA) regions. Prior to US FDA approval, laboratories will be introduced to CARDIO inCode-Score® as an 'In House Assay' for the prevention of heart disease. Following FDA Medical Device approval, the collaboration will extend to manufacturing and sale of the device to laboratories and test centres across the US. A similar approach will be adopted in the EMEA market.

Thermo Fisher Scientific has been chosen as the preferred partner based on the design and development of the CARDIO inCode-Score® test on Thermo Fisher's own QuantStudio™ 5 Dx Real-Time PCR System. The QuantStudio™ 5 Dx Real-Time PCR System is globally available with significant coverage across the US and EMEA region. Increasing demand for CARDIO inCode-Score® will be met by Thermo Fisher Scientfic's scale up of the test manufacturing.

Thermo Fisher Scientific is a major global provider of genetic reagents to labs with installed QuantStudio (QS Dx) platform user base.

The collaboration is on a non-exclusive basis for a 3 year term that is extendable and covers the US and EMEA territories only.  All sales will be through Thermo Fisher Scientific's lab network with end pricing currently still to be agreed. 

The initial approach prior to approval is an "In House Assay" (IHA) whereby Thermo Fisher Scientific introduces GENinCode to labs. Thermo Fisher Scientific manufactures and sells the IHA reagents to labs to perform CARDIO inCode-Score and GENinCode sells the CARDIO inCode-Score license to SITAB system and reporting i.e. SITAB's cloud-based analysis and AI bioinformatics. 

The second phase will be selling the test as a medical device following FDA approval.  Under that approach, Thermo Fisher Scientific introduces GENinCode to labs and manufactures CARDIO inCode-Score as a Medical Device for labs to perform CARDIO inCode-Score. GENinCode sells CARDIO inCode-Score full test system including reporting i.e. SITAB's cloud-based analysis AI bioinformatics.

In both approaches, the Lab will charge for the test directly to the patient/payor at ~$500/test for Medicare and Self-Pay and healthcare provider costs to be determined.

Under the current structure of the Company's own CLIA lab in Irvine undertaking the test itself, GENinCode gets the full test fee (~$500/test) but is responsible for the cost of goods and all overheads of the laboratory and selling.  While the Company sells the test to the labs under the Thermo Fisher deal and therefore receives a lower revenue per test, it expects to improve cost of goods and to have no lab costs and a reduced cost of sales.

The board also believes that the structure provides other benefits beyond the economics with a much greater reach to labs on the Thermo Fisher network, the expectation that these labs will order in bigger test pack sizes and will provide international reach.

Product Portfolio

CARDIO inCode-Score (CIC-SCORE)

CIC-SCORE is GENinCode's flagship product, providing a genetic risk assessment for cardiovascular disease. Traditional cardiovascular risk assessments often underestimate the risk for individuals categorised as low or intermediate risk. CIC-SCORE overcomes this limitation by analysing genetic variants (SNPs) to calculate a Polygenic Risk Score (PRS). When combined with a patient's clinical data, the PRS enables more accurate risk assessment and stratification, enhancing lifetime cardiovascular risk prediction and aiding in the identification of patients at the highest risk of coronary heart disease.  Tests are currently undertaken through the Company's California CLIA laboratory.  The collaboration with Thermo Fisher, will initially facilitate the production of an in house assay for use in any US lab that undertakes genetic testing that can take advantage of SITAB to provide the analysis to make the genetic risk assessment. Following FDA approval the test will  be made available in a kit format to be sold by GENinCode into the Thermo Fisher lab network.

LIPID inCode

LIPID inCode is a genetic diagnostic test that identifies mutations in genes associated with hypercholesterolemia and familial hypercholesterolemia. Early diagnosis and treatment of familial hypercholesterolemia can significantly reduce the risk of atherosclerosis and prevent cardiovascular disease. LIPID inCode also evaluates additional genetic markers to guide treatment decisions for hypercholesterolemia, helping clinicians tailor therapy for prevention of cardiovascular disease. Early diagnosis is vital, as this enables earlier treatment which can lead to a reduced risk of early-onset cardiovascular disease.

THROMBO inCode

THROMBO inCode is a genetic test that evaluates hereditary thrombophilia and the risk of venous thromboembolism (VTE). By analysing genetic variants linked to thrombosis, THROMBO inCode supports the prevention and treatment of thrombosis in individuals with a family history of the condition. The test has been adopted by several hospitals and laboratories in Europe and is underpinned by published clinical research.

Risk of Ovarian Cancer Algorithm (ROCA Test)

The ROCA Test is a surveillance tool for the early detection of ovarian cancer, primarily for individuals with BRCA1 or BRCA2 pathogenic variants who defer risk-reducing surgery. It has been recommended in the latest NICE Guidance as the only surveillance test for familial ovarian cancer and the first to be included in an ovarian cancer care pathway globally. The guidance highlights risk identification, genetic testing, and support through preventive surgery or surveillance using the ROCA Test.

The ROCA Test offers the opportunity of a recurring revenue model through regular monitoring. The Company is in discussions for the adoption of the ROCA Test within the NHS. NICE draft guidelines recommend ROCA testing every four months. Final NICE guidance was released in March 2024 officially recommending the test. This marked a significant milestone for its adoption in clinical pathways. Efforts are underway to roll out the test across several NHS regions with support from Cancer Alliances and Specialised Services. In 2024-2025, targeted NHS roll-out plans began with initial implementations in 4-6 regions. The test has gained strong backing from gynaecological oncologists, geneticists, and genetic counsellors.

International expansion is progressing, with agreements signed in Switzerland and Austria in 2024, and plans for expansion into Germany and Spain following. The US market remains under evaluation, with ongoing considerations based on progress in the UK and Europe.

Growth Strategy

The Company has developed a three-region strategy, targeting the US, the UK and Europe. These present opportunities for growth in each market, particularly the US, which is expected to be a key driver of revenue growth for GENinCode.

US Strategy

The US provides GENinCode's most significant target market opportunity for its genetic testing solutions to improve cardiovascular disease (CVD) prevention and the diagnosis of familial hypercholesterolemia (FH). The US target market for LIPID inCode includes approximately 0.2 million patients with diagnosed FH (but who have not been tested for FH genetic variants) and an estimated 1.3 million undiagnosed probable FH patients. Despite the efforts of the Centres for Disease Control and Prevention (CDC) to prioritize FH for early detection, less than 30% of FH patients in the US have been identified, which the directors believe highlights the need for enhanced diagnostic tools and screening strategies.

LIPID inCode and FH Testing

LIPID inCode is the first commercially available Monogenic + Polygenic test for FH. The test is classified as a 'Tier 1' genomic test by the CDC and provides physicians with a comprehensive diagnostic profile, including monogenic FH diagnosis, polygenic hypercholesterolemia risk, and coronary heart disease risk (via CARDIO inCode). It is estimated that the FH testing market in the US represents a $1.8 billion opportunity.

GENinCode's collaboration with the FH Foundation supports the adoption of LIPID inCode in US primary care settings as part of the DISCOVER FH programme. Funded by a grant from the US Department of Defence (DOD), this initiative focuses on improving early diagnosis of FH and implementing advanced diagnostic tools for both adult and paediatric populations. DISCOVER FH partners include UT Southwestern Medical Centre, University of Pennsylvania, Geisinger, West Virginia University, Mayo Clinic, and the Veterans Association.

CARDIO inCode-Score

CARDIO inCode-Score (CiC-Score) offers a polygenic risk assessment for CVD prevention and is central to GENinCode's US strategy. Once approved, CiC-Score is expected to be the first-in-class kit available for national distribution to US CLIA-certified laboratories. This will allow broader scalability through both service-based testing and distribution of test kits.

Reimbursement Progress

Reimbursement frameworks for LIPID inCode and CARDIO inCode continue to expand. LIPID inCode has established ICD-10 and CPT codes for FH testing, enabling adoption by hospital systems, Integrated Delivery Networks (IDNs) and community clinics. CARDIO inCode has received CPT PLA coding (0401U) approved by the American Medical Association and is included in the CMS 2025 Clinical Lab Fee Schedule with a median price of ~$500 per test. MolDx submission is in preparation to further expand state-based reimbursement following FDA approval. These developments are expected to position GENinCode for rapid growth in adoption and revenue generation.

Commercialisation and Strategic Focus

GENinCode's US commercialisation strategy includes a targeted engagement plan focused on the top 250 US physicians in lipidology and preventive cardiology. The Company is also building partnerships with key opinion leaders (KOLs) and major institutions, supported by education programmes and the SITAB portal. Service-based testing is expanding across institutions, community clinics, and executive health settings. In addition, commercial payer discussions are progressing, focusing on benefits investigation and securing out-of-network coverage.

The Company has now successfully onboarded over 48 top-tier institutional sites (up from 20 in 2024), mainly for the use of LIPID inCode with adoption expected to grow further following CARDIO inCode-Score FDA approval and insurance coverage. The Total Addressable Market (TAM) for CiC-Score is estimated at $10.5 billion, with a Serviceable Available Market (SAM) of $4.5 billion. Initial market scoping indicates an addressable patient pool of 21 million, with 8.5 million likely to be prescribed CiC-Score if covered by insurance.

In December, the Company announced a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test. Sohin Genetics will promote and market the test across its network of hospitals and clinics, leveraging GENinCode's SITAB international reporting system.

UK Strategy

In the UK, GENinCode's commercialisation strategy has focused on delivering and validating the provision of LIPID inCode within the NHS. The Company is building relationships with leading medical institutions and Health Innovation Networks (HINs) to enhance the detection and management of Familial Hypercholesterolemia (FH). FH is an inherited genetic disorder affecting approximately 1 in 250 individuals in the UK, equating to between 230,000 and 260,000 people.

In February 2022, the Company announced the successful completion of its NHS clinical study and positive results for its LIPID inCode test undertaken at the Royal Brompton and Guy's & St Thomas' Trust. This was followed by a successful pilot scheme in partnership with the Academic Health Science Network (AHSN), leading to the adoption of LIPID inCode in the North of England. The NHS has now processed over 2,800 FH tests, helping the NHS Genetic Lab Hub meet its targets for FH detection, a critical element of the NHS Long Term Plan to prevent CVD.

In May 2023, NHS funding was allocated to expand LIPID inCode testing, aiming to improve the diagnosis and treatment of FH. The Directors believe LIPID inCode offers faster turnaround times and reduced costs compared to current NHS testing methods. These improvements align with the NHS Long Term Plan's focus on preventing CVD and improving outcomes, the single largest medical condition for NHS England where lives can be saved.

Additionally, the Company is introducing CARDIO inCode to the NHS, aiming to enhance the risk assessment of coronary heart disease (CHD). The Company continues to advance discussions with other NHS England trusts to broaden the implementation of both LIPID inCode and CARDIO inCode nationwide.

Europe Strategy

GENinCode's key EU products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode already generating revenues, primarily in Spain. Year-on-year revenue growth in Spain is driven by THROMBO inCode and LIPID inCode, supported by Spanish regions' Familial Hypercholesterolemia (FH) detection plans. The regional roll-out of CARDIO inCode for cardiovascular prevention in primary care is contributing to growth with the announcement of the Catalonia roll-out, with pilots underway in the Extremadura region and negotiations ongoing in Andalucía, Madrid and the Basque region.

The Catalonia region in Spain has also adopted CARDIO inCode for primary care cardiovascular risk assessment, targeting a CVD addressable market of approximately 476,000 patients aged 45 to 64. Test volumes are expected to escalate up to approximately 1,000 patient tests through 2025 with volumes expanding as increasing numbers of physicians, community practices and regions are educated and onboarded for testing.

In Italy, direct business operations are expanding with partnerships such as Fondazione SISA supporting LIPID inCode. In Germany, LIPID inCode sales are strengthening through collaboration with Uniklinikum, leveraging the NHS model for implementation.

GENinCode's plans for further expansion in Europe are driven by strategic partnerships, tenders, and regional pilots, ensuring a strong presence in key markets and supporting its broader growth objectives.

Expected Financial Drivers

In assessing the future financial drivers of the business, the Company has made the following assumptions about revenues:

·        In the US, LIPID inCode is expected to reach on average 100 tests per month in 2026, increasing to 230 tests per month in 2027, and sold at circa £450 each (blended price of Insurance and self-pay). CARDIO inCode tests are expected to reach on average 250 tests per month from Q2 2026 (post FDA-approval), increasing to 1,875 tests per month in 2027 and sold at circa £150 each (blended price of distributor and self-pay).

·        In the UK, the Company estimates that each new NHS region would add approximately £650k of revenue annually and assumes the addition of one new region expected in 2027 and two more in 2028.

·        In addition, in Spain, the Company expects the launch of CARDIO inCode Public Health and a new partnership would add £750k in 2026 on top of the normalised 20% annual organic growth.

The Group will have a focus on moving a higher percentage of costs to a variable basis with resources increasingly focused on gaining commercial sales.  However, the labs are fully commissioned and no material capex would be required until the next phase of commercial expansion expected to be in 2027. The Company's cost base is expected to be circa £6.50m in 2026, and circa £7.75m in 2027, reflecting mainly variable cost increases associated with revenue scale-up.

Current trading and Outlook

GENinCode released its unaudited interim results for the period ended 30 June 2025 on 30 September 2025, reporting revenues for the half-year period of £1.60 m (H1 2024: £1.39m), an increase of 15% year-on-year, and an adjusted EBITDA loss, excluding unrealised foreign exchange movements, of £2.07m (H1 2024: £2.05m loss), reflecting a combination of higher revenues, improved margins and containment of operating costs.

For the full year 2025 the Company expects, subject to audit, that revenue will be c£3.1m and a loss of c£5.0m.

The Board remains confident in the Company's commercial progress across its operating geographies and looks forward to scaling revenue growth through its collaboration with Thermo Fisher both before and following FDA approval.

Reasons for the Fundraising

The Group will focus on completion of its US regulatory and reimbursement program whilst driving commercialisation in the US, expanding its activities in the UK and Europe. The objective of the Fundraising will be to scale US revenues and increase traction with the NHS in the UK and expand its EU market.

Use of proceeds of the Fundraising

The use of proceeds will be:

US commercialisation and scale-up program                                                           £1.25m

EU expansion program                                                                               £0.75m

UK Expansion program                                                                               £0.75m

Costs of the fundraising and general working capital                                    £0.75m

Details of the Fundraising

The Placing

The Company intends to raise a minimum of £2.6 million (before expenses) by way of a conditional placing by Cavendish, Oberon and Turner Pope, as agents for the Company, of New Ordinary Shares at the Issue Price pursuant to the Placing Agreement.

The Placing is conditional, amongst other things, on the passing of the Resolutions, the Placing Agreement not having been terminated and Admission occurring on or before 8.00 a.m. on 11 February 2026 (or such later date as the Joint Bookrunners and the Company may agree, being not later than 8.00 a.m. on 27 February 2026).

Under the terms of the Placing Agreement, the Joint Bookrunners, as agents for the Company, have agreed to use their respective reasonable endeavours to procure Placees for the Placing Shares at the Issue Price. The Company has given certain customary warranties to the Joint Bookrunners in connection with the Fundraising and other matters relating to the Company and its business. In addition, the Company has agreed to indemnify the Joint Bookrunners in relation to certain liabilities they may incur in undertaking the Fundraising. The Joint Bookrunners have the right to terminate the Placing Agreement in certain circumstances prior to Admission, in particular, for a breach of any of the warranties. The Placing is not being underwritten.

The Placing Shares will be allotted and credited as fully paid and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or after the date on which they are issued.

The Subscription

The Company proposes to raise £0.9 million (before expenses) by way of a proposed subscription, comprising the issue of up to 87,300,000 Subscription Shares at the Issue Price. The Subscription is not being underwritten.

Certain Directors and Nestor Oller have entered into Subscription Letters to subscribe for an aggregate of 87,300,000 Subscription Shares representing £0.9 million, at the Issue Price. The Subscription is conditional upon (amongst other things) the passing of the Resolutions, the Placing Agreement not having been terminated and Admission occurring on or before 8.00 a.m. on 11 February 2026 (or such later date and/or time as Joint Bookrunners and the Company may agree, being not later than 8.00 a.m. on 27 February 2026).

Placing Agreement

Pursuant to the Placing Agreement, the Joint Bookrunners have agreed to use their reasonable endeavours as agents of the Company to procure subscribers for the Placing Shares. The Placing Agreement provides, inter alia, for payment by the Company to the Joint Bookrunners of a corporate finance fee and also commissions based on certain percentages of the product of the number of Placing Shares placed by them multiplied by the Issue Price. The Company will bear all other expenses of and incidental to the Placing.

The Placing Agreement contains certain warranties and indemnities from the Company in favour of the Joint Bookrunners and the obligations of the Joint Bookrunners under the Placing Agreement in connection with the Placing are conditional, inter alia, upon:

a)   the Resolutions having been passed without any amendment not approved by the Joint Bookrunners by the requisite majority of Shareholders at the General Meeting;

b)   the Placing Agreement having become unconditional in all respects and not having been terminated in accordance with its terms prior to Admission; and

c)   Admission becoming effective not later than 8.00 a.m. on 11 February 2026 or such later time and/or date as the Company and the Joint Bookrunners may agree, being not later than 8.00 a.m. on 27 February 2026.

The Joint Bookrunners may terminate the Placing Agreement in certain circumstances, if, inter alia, the Company has failed to comply or is unable to comply with any of its obligations under the Placing Agreement; if there is a material adverse change in the condition (financial, operational, legal or otherwise), earnings, business or operations of the Company or the Group; or if there is a change in financial, political, economic or stock market conditions, which in their opinion (acting in good faith) would or would be likely to prejudice materially the Company or the Fundraising.

The Retail Offer

The Company values its retail Shareholder base and believes that it is appropriate to provide the retail community resident in the United Kingdom the opportunity to participate in the Retail Offer at the Issue Price.

On the terms set out in a separate announcement made following the issue of the Announcement, the Company is using WRAP platform to conduct an offer for subscription of up to 50,000,000 Retail Offer Shares. Members of the public in the UK can access the Retail Offer through Winterflood/WRAP's extensive partner network of investment platforms, retail brokers and wealth managers, subject to such partners' participation. For further information on the Retail Offer, please refer to the relevant announcement on 21 January 2026.

The Retail Offer is conditional on the Placing and Subscription being completed and Admission taking effect. The Retail Offer will, if taken up in full, result in the issue of 50,000,000 new Ordinary Shares representing approximately 7.3 per cent. of the Enlarged Share Capital.

Settlement and Dealings

The New Ordinary Shares, when issued, will be fully paid and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Application will be made to the London Stock Exchange for admission of the New Ordinary Shares to trading on AIM. It is expected that Admission will take place on or before 8.00 a.m. on 11 February 2026 and that dealings will commence at the same time.

In accordance with the provisions of the Disclosure and Transparency Rules of the FCA, the Company confirms that, immediately following Admission, its issued share capital will comprise 686,882,042 Ordinary Shares of 1 pence each (assuming full take up of the Retail Offer). All Ordinary Shares shall have equal voting rights and, following the Fundraising, none of the Ordinary Shares will be held in treasury. The total number of voting rights in the Company immediately following Admission would therefore be 686,882,042 (assuming full take up of the Retail Offer).

Participation of the Directors in the Fundraising

As outlined above certain Directors have agreed to subscribe for New Ordinary Shares pursuant to the Fundraising. The number of New Ordinary Shares subscribed for by each Director and their resulting shareholdings upon Admission are set out below:

(1)  The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.

(2)  Assuming the Retail Offer is subscribed in full and a minimum of £3.5 million is raised by way of Placing and Subscription.

Related party transactions

Where a company enters into a related party transaction, under the AIM Rules the independent directors of the company are required, after consulting with the company's nominated adviser, to state whether, in their opinion, the transaction is fair and reasonable in so far as its shareholders are concerned.

The participation by certain Directors in the Fundraising as outlined above constitute related party transactions pursuant to Rule 13 of the AIM Rules. William Rhodes as independent director, having consulted with the Company's nominated adviser, Cavendish, consider that the terms of the participation in the Fundraising by Jordi Puig, Matthew Walls, Sergio Olivero, Paul Foulger, Huon Gray, Felix Frueh is fair and reasonable insofar as the Company's Shareholders are concerned.

The Nestor Oller entities and Maven Income and Growth VCTs

The Nestor Oller entities are an undertaking controlled by Nestor Oller, who also controls Santi 1990 SL which is a substantial Shareholder in the Company as it holds 12.41% of the Existing Ordinary Shares. Furthermore, Maven Income and Growth VCTs are a substantial Shareholder in the Company as it holds 11.38% of the Existing Ordinary Shares.

Consequently, the Nestor Oller entities and Maven Income and Growth VCTs are considered to be related parties of the Company for the purposes of Rule 13 of the AIM Rules for Companies. The Nestor Oller entities is subscribing for 65,800,000 Subscription Shares under the Subscription and Maven Income and Growth VCTs are subscribing for 25,000,000 Placing Shares.

The subscriptions by the Nestor Oller entities and Maven Income and Growth VCTs constitute related party transactions for the purposes of the AIM Rules for Companies. The Directors who are independent of these transactions, being William Rhodes, Jordi Puig, Matthew Walls, Sergio Olivero, Paul Foulger, Huon Gray, Felix Frueh, having consulted with the Company's nominated adviser, Cavendish Capital Markets Limited, consider that that the participation in the Fundraising by the Nestor Oller entities and Maven Income and Growth VCTs are fair and reasonable insofar as the Shareholders are concerned.

General Meeting

A notice convening the General Meeting to be held at Cavendish Capital Markets Limited, 1 Bartholomew Close, London, EC1A 7BL on 9 February 2026 at 11:00 a.m. will be set out in Part II of the Circular.

Recommendation

The Directors consider the Fundraising to be in the best interests of the Company and its Shareholders as a whole. 

Accordingly, the Directors unanimously recommend that all Shareholders vote in favour of the Resolutions as they intend to do, or procure to be done, in respect of their own beneficial shareholdings and their related parties, being, in aggregate, 36,669,344 Ordinary Shares as at 20 January 2026 Ordinary Shares, representing approximately 12.78 per cent. of the Existing Issued Share Capital.

Yours faithfully

William Rhodes

Non-Executive Chairman

EXPECTED TIMETABLE

Notes:

1.        Each of the above times and/or dates is subject to change at the absolute discretion of the Company and Cavendish. If any of the above times and/or dates should change, the revised times and/or dates will be announced through a Regulatory Information Service.

2.        All of the above times refer to London time unless otherwise stated.

3.        All events listed in the above timetable following the General Meeting are conditional on the passing of the Resolutions at the General Meeting.

DEFINITIONS

The following definitions apply throughout this Announcement unless the context otherwise requires:

APPENDIX II

TERMS AND CONDITIONS OF THE PLACING

IMPORTANT INFORMATION FOR INVITED PLACEES ONLY

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE TERMS AND CONDITIONS SET OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT") ARE DIRECTED ONLY AT PERSONS WHOSE ORDINARY ACTIVITIES INVOLVE THEM  ACQUIRING, HOLDING, MANAGING AND DISPOSING OF INVESTMENTS (AS PRINCIPAL OR AGENT) FOR THE PURPOSES OF THEIR BUSINESS AND WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND ARE: (1) IF IN A MEMBER STATE OF THE EUROPEAN ECONOMIC AREA ("EEA"), QUALIFIED INVESTORS AS DEFINED IN ARTICLE 2(e) OF THE PROSPECTUS REGULATION (EU) 2017/1129 AS AMENDED FROM TIME TO TIME (THE "EU PROSPECTUS REGULATION") ("EU QUALIFIED INVESTORS"); (2) IF IN THE UNITED KINGDOM, ARE QUALIFIED INVESTORS WITHIN THE MEANING OF PARAGRAPH 15 OF PART 2 OF SCHEDULE 1 OF THE PUBLIC OFFERS AND ADMISSIONS TO TRADING REGULATIONS 2024  (THE "POATR") ("UK QUALIFIED INVESTORS") AND WHO ALSO (A) FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") (INVESTMENT PROFESSIONALS) OR (B) FALL WITHIN ARTICLE 49(2)(a) TO (d) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE ORDER; OR (3) ARE PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").

THIS ANNOUNCEMENT AND THE INFORMATION IN IT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS.

DISTRIBUTION OF THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED OR PROHIBITED BY LAW OR REGULATION. PERSONS DISTRIBUTING THIS ANNOUNCEMENT MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO.

THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR THE SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY.

The Placing Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of the Placing Shares is being made in the United States. The Placing is being made solely outside the United States to persons in offshore transactions (as defined in Regulation S under the Securities Act ("Regulation S")) meeting the requirements of Regulation S. Persons receiving this Announcement (including custodians, nominees and trustees) must not forward, distribute, mail or otherwise transmit it in or into the United States or use the United States mails, directly or indirectly, in connection with the Placing.

This Announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Placing Shares in any Restricted Jurisdiction. This announcement and the information contained herein are not for publication or distribution, directly or indirectly, to persons in a Restricted Jurisdiction unless permitted pursuant to an exemption under the relevant local law or regulation in any such jurisdiction. No action has been taken by the Company, Cavendish Capital Markets Limited ("Cavendish"), Oberon Investments Limited ("Oberon"), Turner Pope Investments (TPI) Ltd ("TPI" and together with "Cavendish" and "Oberon", the "Placing Agents" and each a "Placing Agent") or Placing Agent Affiliates (as defined below) or GENinCode Affiliates (as defined below) that would permit an offer of the Placing Shares or possession or distribution of this Announcement or any other publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required. Persons receiving this Announcement are required to inform themselves about and to observe any such restrictions.

All offers of the Placing Shares will be made under an exception to the prohibition on offers to the public under the POATRs, and also pursuant to an exemption under the FCA's Prospectus Rules: Admission to Trading on a Regulated Market sourcebook ("PRM") and the EU Prospectus Regulation from the requirement to produce a prospectus. The Placing Shares have not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission or other regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of the Placing or the accuracy or adequacy of this Announcement. Any representation to the contrary is a criminal offence in the United States. The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada, no prospectus has been lodged with, or registered by, the Australian Securities and Investments Commission or the Japanese Ministry of Finance; the relevant clearances have not been, and will not be, obtained for the South Africa Reserve Bank or any other applicable body in the Republic of South Africa in relation to the Placing Shares and the Placing Shares have not been, nor will they be, registered under or offered in compliance with the securities laws of any state, province or territory of Australia, Canada, Japan, or the Republic of South Africa. Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction outside the United Kingdom.

Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this Announcement should seek appropriate advice before taking any action.

Any indication in this Announcement of the price at which the existing ordinary shares in the capital of the Company have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser.

No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this Announcement.

By participating in the Placing, each person who is invited to and who chooses to participate in the Placing (a "Placee") by making or accepting an oral and/or written legally binding offer to subscribe for Placing Shares is deemed to have read and understood this Announcement in its entirety (including this Appendix) and to be providing the representations, warranties, undertakings, agreements and acknowledgements contained herein.

EACH PLACEE SHOULD CONSULT WITH ITS OWN ADVISERS AS TO LEGAL, REGULATORY, TAX, BUSINESS AND RELATED ASPECTS OF A SUBSCRIPTION FOR PLACING SHARES.

Details of the Placing Agreement and the Placing Shares

The Company has today entered into the placing agreement with Cavendish (the Company's Nominated Adviser, broker and joint bookrunner in connection with the Placing), Oberon and TPI (the Company's joint bookrunners in connection with the Placing) (the "Placing Agreement"). Pursuant to the Placing Agreement, the Placing Agents have, subject to the terms and conditions set out therein, agreed to use reasonable endeavours, as agents of the Company, to procure subscribers for the Placing Shares pursuant to the bookbuilding process described in this Announcement and as set out in the Placing Agreement ("Bookbuilding Process").

The Placing is not being underwritten.

The Placing Shares will, when issued, be subject to the articles of association of the Company (the "Articles"), be credited as fully paid and rank pari passu in all respects with each other and with the existing ordinary shares in the capital of the Company then in issue, including the right to receive all dividends and other distributions declared, made or paid in respect of the ordinary shares of the Company after the date of Admission.

The Placing Shares will be issued free of any encumbrance, lien or other security interest.

Application for admission to trading on AIM

Application will be made to the London Stock Exchange for the Placing Shares to be admitted to AIM. Subject to the satisfaction or waiver of the conditions of the Placing Agreement ("Conditions"), it is expected that Admission will take place and dealings in the Placing Shares will commence on AIM on or around 8.00 a.m. on 11 February 2026.

Bookbuilding Process

Commencing today, the Placing Agents will be conducting the Bookbuilding Process to determine demand for participation in the Placing by Placees. This Announcement gives details of the terms and conditions of, and the mechanics of participation in, the Placing. However, the Placing Agents will be entitled to effect the Placing by such alternative method to the Bookbuilding Process as they may, after consultation with the Company, determine. No commissions will be paid by or to Placees in respect of any participation in the Placing or subscription for Placing Shares.

Participation in, and principal terms of, the Bookbuilding Process

Participation in the Placing is by invitation only and will only be available to persons who may lawfully be, and are, invited to participate by the Placing Agents. The Placing Agents and Placing Agent Affiliates (as defined below) are entitled to participate as Placees in the Bookbuilding Process.

The Bookbuilding Process will establish the number of Placing Shares to be issued pursuant to the Placing.

The book will open with immediate effect. The Bookbuilding Process is expected to close not later than 7.00 a.m. on 22 January 2026, but may be closed at such earlier or later time as the Placing Agents may, acting jointly, in their absolute discretion (after consultation with the Company), determine. The announcement containing the results of the accelerated bookbuild will be released following the close of the Bookbuilding Process.

A bid in the Bookbuilding Process will be made on the terms and conditions in this Appendix and will be legally binding on the Placee on behalf of which it is made and, except with the Placing Agents' consent, will not be capable of variation or revocation after the close of the Bookbuilding Process.

A Placee who wishes to participate in the Bookbuilding Process should communicate its bid by telephone to its usual sales contact at the relevant Placing Agent. Each bid should either state the number of Placing Shares which the prospective Placee wishes to subscribe for or a fixed monetary amount at, in either case, the Issue Price. If successful, the relevant Placing Agent will re-contact and confirm orally to Placees following the close of the Bookbuilding Process the size of their respective allocations and a trade confirmation will be despatched as soon as possible thereafter. The relevant Placing Agent's oral confirmation of the size of allocations will constitute an irrevocable legally binding agreement in favour of the Company and the relevant Placing Agent pursuant to which each such Placee will be required to accept the number of Placing Shares allocated to the Placee at the Issue Price on the terms and subject to the conditions set out herein and in accordance with the Articles. Each Placee's allocation and commitment will be evidenced by a trade confirmation issued to such Placee by the relevant Placing Agent. The terms of this Appendix will be deemed incorporated in that trade confirmation.

The Placing Agents reserve the right to scale back the number of Placing Shares to be subscribed by any Placee in the event that the Placing is oversubscribed. The Placing Agents also reserve the right not to accept offers to subscribe for Placing Shares or to accept such offers in part rather than in whole. The acceptance and, if applicable, scaling back of offers shall be at the absolute discretion of the Placing Agents and the Company.

Each Placee's obligations will be owed to the Company and to the relevant Placing Agent. Following the oral confirmation referred to above, each Placee will also have an immediate, separate, irrevocable and binding obligation, owed to the Company and the relevant Placing Agent, as agent of the Company, to pay to (or as the relevant Placing Agent may direct) in cleared funds an amount equal to the product of the Issue Price and the number of Placing Shares allocated to such Placee.

To the fullest extent permissible by law, none of the Placing Agents, any holding company of the Placing Agents, any subsidiary of the Placing Agents, any subsidiary of any such holding company, any branch, affiliate or associated undertaking of any such company nor any of their respective directors, officers and employees (each a "Placing Agent Affiliate") nor any person acting on their behalf shall have any liability to Placees (or to any other person whether acting on behalf of a Placee or otherwise). In particular, none of the Placing Agents, any Placing Agent Affiliate nor any person acting on their behalf shall have any liability (including, to the extent legally permissible, any fiduciary duties), in respect of their conduct of the Bookbuilding Process or of such alternative method of effecting the Placing as the Placing Agents may determine.

All times and dates in this Announcement may be subject to amendment. The Placing Agents shall notify the Placees and any person acting on behalf of the Placees of any changes.

Information to Distributors

Solely for the purposes of the product governance requirements contained within the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Rules"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Rules) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail clients, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in the FCA Handbook Conduct of Business Sourcebook ("COBS"); and (ii) eligible for distribution through all distribution channels as are permitted by EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II") (the "UK Target Market Assessment").

Solely for the purposes of the product governance requirements contained within: (a) MiFID II; (b) Articles 9 and 10 of Commission Delegated Directive EU 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "EU Target Market Assessment" and, together with the UK Target Market Assessment, the "Target Market Assessments").

Notwithstanding the Target Market Assessments, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.  The Target Market Assessments are without prejudice to the requirements of any contractual, legal or regulatory selling restrictions to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessments, the Placing Agents will only procure investors who meet the criteria of professional clients or eligible counterparties. 

For the avoidance of doubt, the Target Market Assessments do not constitute: (a) an assessment of suitability or appropriateness for the purposes of COBS (for the purposes of the UK Target Market Assessment) or MiFID II (for the purposes of the EU Target Market Assessment); or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares. 

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

Persons who are invited to and who choose to participate in the Placing, by making an oral and legally binding offer to acquire Placing Shares will be deemed to have read and understood this Announcement in its entirety and to be making such offer to acquire Placing Shares on the terms and conditions, and to be providing the representations, warranties, acknowledgements and undertakings contained in this Appendix.

In this Appendix, unless the context otherwise requires, "Placee" means a Relevant Person (including individuals, funds or others) by whom or on whose behalf a commitment to take up Placing Shares has been given and who has been invited to participate in the Placing by a Placing Agent.

All obligations of the Placing Agents under the Placing will be subject to fulfilment of the conditions referred to in this Announcement including without limitation those referred to below under "Conditions of the Placing".

Conditions of the Placing

The Placing is conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.

The obligations of the Placing Agents under the Placing Agreement are conditional, amongst other things, on:

1.       the placing results announcement being released at the relevant time;

2.       the warranties on the part of the Company contained in the Placing Agreement being true and accurate and not misleading on and as of the date of the Placing Agreement and at all times during the period up to and including the date of Admission; 

3.       the Placing Shares having been allotted, conditional only on Admission;

4.       the Subscription Shares having been allotted, conditional only on Admission, and payment for such Subscription Shares having been received by the Company prior to Admission;

5.       the Company raises a minimum of £3.5 million pursuant to the Placing and Subscription;

6.       the performance by the Company in all material respects of its obligations under the Placing Agreement to the extent that they fall to be performed prior to Admission;

7.       there not occurring, in the opinion of the Placing Agents (acting in good faith), a material adverse change, or any development reasonably likely to involve a prospective material adverse change, in the condition (financial, operational, legal or otherwise) or the earnings, business affairs or business prospects of the Company or the Group which is material in the context of the Group taken as a whole, whether or not arising in the ordinary course of business and whether or not foreseeable at the date of the Placing Agreement;

8.       the general meeting of the Company having taken place on the date set out in the notice of general meeting and each of the resolutions having been passed thereat by the requisite majority; and

9.       Admission occurring not later than 8.00 a.m. on or around 11 February 2026 or such later time and/or date as the Placing Agents may agree in writing with the Company (but in any event no later than 8.00 a.m. on 27 February 2026). 

If (a) the Conditions of the Placing are not fulfilled (or to the extent permitted under the Placing Agreement waived by the Placing Agents), or (b) the Placing Agreement is terminated in the circumstances specified below, the Placing will lapse and each Placee's rights and obligations hereunder shall cease and determine at such time and no claim may be made by a Placee in respect thereof. None of the Placing Agents, the Company, any Placing Agent Affiliate, nor any holding company of the Company, any subsidiary of the Company, any subsidiary of any such holding company, any branch, affiliate or associated undertaking of any such company nor any of their respective directors, officers and employees (each a "GENinCode Affiliate") shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision it may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition in the Placing Agreement or in respect of the Placing generally.

By participating in the Placing, each Placee agrees that the Placing Agents' rights and obligations in respect of the Placing terminate, inter alia, in the circumstances described below under "Right to terminate under the Placing Agreement".

Right to terminate under the Placing Agreement

Each Placing Agent may, at any time before Admission and in its absolute discretion, by notice in writing to the Company (or by orally communicating the same to any director of the Company), terminate the Placing Agreement with immediate effect if, amongst other things:

1.       any statement contained in the Placing Documents is, or has become, or has been discovered to be untrue, incorrect or misleading in any material respect;

2.       any of the warranties, was, when given, or becomes, untrue, inaccurate or misleading;

3.       the Company has failed to or is unable to comply with any of its obligations under the Placing Agreement;

4.       trading in the Company's shares on AIM is suspended or cancelled; 

5.       the appointment of the Placing Agents as agents of the Company is terminated for whatever reason;

6.       in the opinion of a Placing Agent (acting in good faith), there has been a material adverse change or any development reasonably likely to involve a prospective material adverse change (including, but not limited to, the deterioration of the health of any key member of management of the Company), in the condition (financial, operational, legal or otherwise) or the earnings, business affairs or business prospects of the Company or the Group which is material in the context of the Group as a whole taken as a whole, whether or not arising in the ordinary course of business and whether or not foreseeable at the date of Placing Agreement, since the date of the Placing Agreement; and

7.       in the opinion of a Placing Agent (acting in good faith), there has been, (i) any change, or development involving a prospective change, in national or international, military, diplomatic, monetary, economic, political, financial, industrial or market conditions or exchange rates or exchange controls, or any incident of terrorism or outbreak or escalation of hostilities or any declaration by the UK or the US of a national emergency or war or any other calamity or crisis whether or not foreseeable at the date of this Agreement, (ii) a suspension of trading in securities generally on the London Stock Exchange or New York Stock Exchange or trading is limited or minimum prices established on any such exchange; (iii) a declaration of a banking moratorium in London or by the US federal or New York State authorities or any material disruption to commercial banking or securities settlement or clearance services in the US or the UK, which would or would be likely to prejudice materially the Company or the Fundraising, or make the success of the Fundraising doubtful or makes it impracticable or inadvisable to proceed with the Fundraising, or render the creation of a market in the ordinary share capital of the Company temporarily or permanently impracticable.

By participating in the Placing, each Placee agrees with the Placing Agents that the exercise by the Placing Agents of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of the Placing Agents and that the Placing Agents need not make any reference to the Placees in this regard and that, to the fullest extent permitted by law, neither the Company, the Placing Agents, any Placing Agent Affiliate nor any GENinCode Affiliate shall have any liability whatsoever to the Placees in connection with any such exercise or failure to so exercise.

Any termination by a Placing Agent of its rights under the Placing Agreement shall be without prejudice to the obligations (if any) and rights of the other Placing Agents and, if such a Placing Agent so elects, the Placing Agreement shall continue in full force and effect. In the event of a Placing Agent terminating its rights under the Placing Agreement, no consents or approvals in respect of the Placing shall be required of that Placing Agent.

No Prospectus

No offering document or prospectus has been or will be prepared in relation to the Placing and no such prospectus is required (in accordance with the EU Prospectus Regulation or the PRM) to be published or submitted to be approved by the Financial Conduct Authority ("FCA") and Placees' commitments will be made solely on the basis of the information contained in this Announcement. In the United Kingdom, this Announcement is being directed solely at and distributed and communicated solely to persons in circumstances in which section 21(1) of the Financial Services and Markets Act 2000 (as amended) does not apply.

Each Placee, by accepting a participation in the Placing, agrees that the content of this Announcement is exclusively the responsibility of the Company and confirms to the Placing Agents and the Company that it has neither received nor relied on any information, representation, warranty or statement made by or on behalf of the Placing Agents (other than the amount of the relevant Placing participation in the oral confirmation given to Placees and the trade confirmation referred to below), any Placing Agent Affiliate, any persons acting on its or their behalf or the Company or any Placing Agent Affiliate and none of the Placing Agents, any Placing Agent Affiliate, any persons acting on their behalf, the Company, any GENinCode Affiliate nor any persons acting on their behalf will be liable for the decision of any Placee to participate in the Placing based on any other information, representation, warranty or statement which the Placee may have obtained or received (regardless of whether or not such information, representation, warranty or statement was given or made by or on behalf of any such persons). By participating in the Placing, each Placee acknowledges to and agrees with each Placing Agent for itself and as agent for the Company that, except in relation to the information contained in this Announcement, it has relied on its own investigation of the business, financial or other position of the Company in deciding whether to participate in the Placing. Nothing in this paragraph shall exclude the liability of any person for fraudulent misrepresentation.

Registration and settlement

Settlement of transactions in the Placing Shares following Admission will take place within the CREST system, using the DVP mechanism, subject to certain exceptions. The Placing Agents reserve the right to require settlement for and delivery of the Placing Shares to Placees by such other means as the Placing Agents  may deem necessary, including, without limitation, if delivery or settlement is not possible or practicable within the CREST system within the timetable set out in this Announcement or would not be consistent with the regulatory requirements in the Placee's jurisdiction.

The expected timetable for settlement will be as follows:

Each Placee allocated Placing Shares in the Placing will be confirmed by a Placing Agent either orally or in writing via a contract note or a trade confirmation stating the number of Placing Shares allocated to it, the Issue Price, the aggregate amount owed by such Placee to the relevant Placing Agent and settlement instructions. Placees should settle against the relevant CREST ID shown above. It is expected that such trade confirmation will be despatched on the expected trade date shown above. Each Placee agrees that it will do all things necessary to ensure that delivery and payment is completed in accordance with either the standing CREST or certificated settlement instructions which it has in place with the relevant Placing Agent.

It is expected that settlement will take place on the Settlement Date shown above on a DVP basis in accordance with the instructions set out in the trade confirmation unless otherwise notified by any Placing Agent.

Interest is chargeable daily on payments not received from Placees on the due date in accordance with the arrangements set out above, in respect of either CREST or certificated deliveries, at the rate of two percentage points above the base rate of Barclays Bank Plc as determined by the Placing Agents.

Each Placee is deemed to agree that if it does not comply with these obligations, the relevant Placing Agent may sell any or all of the Placing Shares allocated to the Placee on such Placee's behalf and retain from the proceeds, for the relevant Placing Agent's own account and profit, an amount equal to the aggregate amount owed by the Placee plus any interest due. The Placee will, however, remain liable for any shortfall below the aggregate amount owed by such Placee and it may be required to bear any stamp duty or stamp duty reserve tax (together with any interest or penalties) which may arise upon the sale of such Placing Shares on such Placee's behalf.

If Placing Shares are to be delivered to a custodian or settlement agent, the Placee should ensure that the trade confirmation is copied and delivered immediately to the relevant person within that organisation.

Insofar as Placing Shares are registered in the Placee's name or that of its nominee or in the name of any person for whom the Placee is contracting as agent or that of a nominee for such person, such Placing Shares will, subject as provided below, be so registered free from any liability to any levy, stamp duty or stamp duty reserve tax. If there are any circumstances in which any other stamp duty or stamp duty reserve tax is payable in respect of the issue of the Placing Shares, neither the Placing Agents nor the Company shall be responsible for the payment thereof. Placees will not be entitled to receive any fee or commission in connection with the Placing.

Representations, warranties and terms

By submitting a bid and/or participating in the Placing, each prospective Placee (and any person acting on such Placee's behalf) represents, warrants, undertakes, acknowledges, understands and agrees (for itself and for any such prospective Placee) in favour of the Placing Agents and the Company that (save where the Placing Agents expressly agree in writing to the contrary):

1.       it has read and understood this Announcement in its entirety (including this Appendix) and acknowledges that its participation in the Placing and the issue of the Placing Shares will be governed by the terms of this Announcement (including this Appendix);

2.       no prospectus or offering document has been or will be prepared in connection with the Placing and it has not received and will not receive a prospectus or other offering document in connection with the Bookbuilding Process, the Placing or the Placing Shares or is required under the EU Prospectus Regulation or the PRM;

3.       to indemnify on an after-tax basis and hold harmless each of the Company, the Placing Agents, Placing Agent Affiliates and GENinCode Affiliates and any person acting on their behalf from any and all costs, losses, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the representations, warranties, acknowledgements, agreements and undertakings in this Announcement and further agrees that the provisions of this Announcement shall survive after completion of the Placing;

4.       the Placing Shares will be admitted to AIM and the Company is therefore required to publish and has published certain business and financial information in accordance with the AIM Rules and the UK version of the Market Abuse Regulation (EU 596/2014) which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR") and other applicable laws and regulations (the "Exchange Information"), which includes the Company's announcements and circulars published in the past 12 months, and that the Placee is able to obtain or access this Exchange Information without undue difficulty and is aware of and has reviewed the contents of the Exchange Information;

5.       none of the Placing Agents, any Placing Agent Affiliate or any person acting on their behalf has provided, and will not provide, it with any material or information regarding the Placing Shares or the Company; nor has it requested any of the Placing Agents, nor any Placing Agent Affiliate nor any person acting on their behalf to provide it with any such material or information; 

6.       (i) none of the Placing Agents or any Placing Agent Affiliate or any person acting on behalf of any of them is making any recommendations to it, advising it regarding the suitability of any transactions it may enter into in connection with the Placing and that participation in the Placing is on the basis that it is not and will not be a client of any Placing Agent and that no Placing Agent has any duties or responsibilities to it (or any person acting on behalf of a Placee) for providing the protections afforded to its clients or for providing advice in relation to the Placing nor in respect of any representations, warranties, undertakings, agreements or indemnities contained in the Placing Agreement nor for the exercise or performance of any of its rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right, and (ii) neither it nor, as the case may be, its clients expect any Placing Agent to have any duties or responsibilities to it similar or comparable to the duties of "best execution" and "suitability" imposed by the Conduct of Business Sourcebook contained in the FCA's Handbook of Rules and Guidance, and that no Placing Agent is acting for it or its clients, and that no Placing Agent will be responsible to any person other than the Company for providing protections afforded to its clients;

7.       the content of this Announcement is exclusively the responsibility of the Company and that none of the Placing Agents, nor any Placing Agent Affiliate nor any person acting on their behalf will be responsible for or shall have any liability for any information, representation or statement relating to the Company contained in this Announcement or any information previously published by or on behalf of the Company. None of the Placing Agents, nor any Placing Agent Affiliate nor any person acting on their behalf will be liable for any Placee's decision to participate in the Placing based on any information, representation or statement contained in this Announcement or otherwise. Each Placee further represents, warrants and agrees that the only information on which it is entitled to rely and on which such Placee has relied in committing to subscribe for the Placing Shares is contained in this Announcement, such information being all that it deems necessary to make an investment decision in respect of the Placing Shares, and that it has relied on its own investigation with respect to the Placing Shares and the Company in connection with its decision to subscribe for the Placing Shares and acknowledges that it is not relying on any other information whatsoever and in particular it is not relying on any investigation that any Placing Agent, any Placing Agent Affiliate or any person acting on their behalf may have conducted with respect to the Placing Shares or the Company and none of such persons has made any representations to it, express or implied, with respect thereto;

8.       it has knowledge and experience in financial, business and international investment matters as is required to evaluate the merits and risks of subscribing for the Placing Shares. It further acknowledges that it is experienced in investing in securities of this nature and is aware that it may be required to bear, and is able to bear, the economic risk of, and is able to sustain, a complete loss in connection with the Placing. It has had sufficient time to consider and conduct its own investigation in connection with its subscription for the Placing Shares, including all tax, legal and other economic considerations and has relied upon its own examination of, and due diligence on, the Company, and the terms of the Placing, including the merits and risks involved; 

9.       unless paragraph 10 applies, it has neither received nor relied on any inside information for the purposes of UK MAR and section 56 of the Criminal Justice Act 1993 (the "CJA") in relation to the Company or its participation in the Placing;

10.      if it has received any inside information (for the purpose of UK MAR and section 56 of the CJA) in relation to the Company and its securities in advance of the Placing, it has consented to receive inside information for the purposes of UK MAR and the CJA and it acknowledges that it was an insider or a person who has received a market sounding for the purpose of such legislation and it confirms that it has not: (a) dealt (or attempted to deal) in the securities of the Company (or cancelled or amended an order in relation thereto); (b) encouraged, recommended or induced another person to deal in the securities of the Company (or to cancel or amend an order in relation thereto); and (c) unlawfully disclosed inside information to any person, in each case, prior to the information being made publicly available;

11.      it is not entitled to rely on any information (including, without limitation, any information contained in any management presentation given in relation to the Placing) other than that contained in this Announcement (including this Appendix) and any Exchange Information and represents and warrants that it has not relied on any representations relating to the Placing, the Placing Shares or the Company other than the information contained in this Announcement or in any Exchange Information;

12.      it has not relied on any information relating to the Company contained in any research reports prepared by any Placing Agent or any Placing Agent Affiliate or any person acting on their behalf and understands that (i) none of the Placing Agents, nor any Placing Agent Affiliate nor any person acting on their behalf has or shall have any liability for any public information relating to the Company; (ii) none of the Placing Agents, nor any Placing Agent Affiliate, nor any person acting on their behalf has or shall have any liability for any additional information that has otherwise been made available to such Placee, whether at the date of publication, the date of this Announcement or otherwise; and that (iii) none of the Placing Agents, nor any Placing Agent Affiliate, nor any person acting on their behalf makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of such information, whether at the date of publication, the date of this Announcement or otherwise; 

13.      (i) it is entitled to acquire the Placing Shares for which it is subscribing under the laws and regulations of all relevant jurisdictions which apply to it; (ii) it has fully observed such laws and regulations and obtained all such governmental and other guarantees and other consents and authorities (including, without limitation, in the case of a person acting on behalf of a Placee, all necessary consents and authorities to agree to the terms set out or referred to in this Appendix) which may be required or necessary in connection with its subscription for Placing Shares and its participation in the Placing and has complied with all other necessary formalities in connection therewith; (iii) it has all necessary capacity and authority to commit to participation in the Placing and to perform its obligations in relation thereto and will honour such obligations; (iv) it has paid any issue, transfer or other taxes due in connection with its subscription for Placing Shares and its participation in the Placing in any territory; and (v) it has not taken any action which will or may result in the Company, the Placing Agents or any Placing Agent Affiliate or GENinCode Affiliate or any person acting on their behalf being in breach of the legal and/or regulatory requirements of any territory in connection with the Placing;

14.      it will not distribute, forward, transfer or otherwise transmit this Announcement or any part of it, or any other presentational or other materials concerning the Placing in or into or from the United States (including electronic copies thereof) to any person, and it has not distributed, forwarded, transferred or otherwise transmitted any such materials to any person;

15.      it understands that the Placing Shares have not been and will not be registered under the Securities Act or under the securities laws of any state or other jurisdiction of the United States and are not being offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act;

16.      its acquisition of the Placing Shares has been or will be made in an "offshore transaction" as defined in and pursuant to Regulation S;

17.      it will not offer or sell, directly or indirectly, any of the Placing Shares in the United States except in accordance with Regulation S or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act;

18.      if it is a financial intermediary, any Placing Shares acquired by it in the Placing have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in the United Kingdom other than UK Qualified Investors or in circumstances in which the prior consent of the Placing Agents has been given to the offer or resale;

19.      if it is a financial intermediary, as that term is used in Article 5(1) of the EU Prospectus Regulation: (i) the Placing Shares acquired by it in the Placing have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any member state of the EEA or to which the EU Prospectus Regulation otherwise applies other than EU Qualified Investors or in circumstances in which the prior consent of the Placing Agents has been given to the offer or resale; or (ii) where Placing Shares have been acquired by it on behalf of persons in any member state of the EEA other than EU Qualified Investors, the offer of those Placing Shares to it is not treated under the EU Prospectus Regulation as having been made to such persons;

20.      it has not offered or sold and will not offer or sell any Placing Shares to the public in any member state of the EEA or the United Kingdom except in circumstances falling within Article 1(4) of the EU Prospectus Regulation or Part 1 of Schedule 1 of the POATR which do not result in any requirement for the publication of a prospectus pursuant to Article 3 of the EU Prospectus Regulation or contravene regulation 12 of POATR;

21.      it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) relating to the Placing Shares in circumstances in which it is permitted to do so pursuant to section 21 of FSMA and agrees that this Announcement has not been approved by a Placing Agent in its capacity as an authorised person under section 21 of the FSMA and it may not therefore be subject to the controls which would apply if it was made or approved as financial promotion by an authorised person;

22.      it has complied and will comply with all applicable provisions of FSMA with respect to anything done by it in relation to the Placing Shares in, from or otherwise involving, the United Kingdom;

23.      it has complied with its obligations: (i) under the CJA and UK MAR; (ii) in connection with the laws of all relevant jurisdictions which apply to it and it has complied, and will fully comply, with all such laws (including where applicable, the Criminal Justice Act 1988, the Terrorism Act 2000, the Anti-Terrorism, Crime and Security Act 2001, the Proceeds of Crime Act 2002 (as amended), the Terrorism Act 2006, the Counter-Terrorism Act 2008 and the Money Laundering, Terrorist Financing and Transfer of Funds (Information on the Payer) Regulations 2017) and that it is not a person: (a) with whom transactions are prohibited under the Foreign Corrupt Practices Act 1977 or any economic sanction programmes administered by, or regulations promulgated by, the Office of Foreign Assets Control of the U.S. Department of the Treasury; (b) named on the Consolidated List of Financial Sanctions Targets maintained by HM Treasury of the United Kingdom; or (c) subject to financial sanctions imposed pursuant to a regulation of the European Union or a regulation adopted by the United Nations ((i), (ii), (a) and (b), together, the "Regulations") and rules and guidance on anti-money laundering produced by the FCA and, if it is making payment on behalf of a third party, that satisfactory evidence has been obtained and recorded by it to verify the identity of the third party as required by the Regulations; and it is permitted to subscribe for Placing Shares in accordance with the laws of all relevant jurisdictions which apply to it and it has complied, and will fully comply, with all such laws (including where applicable, the Anti-Terrorism, Crime and Security Act 2001, the Terrorism Act 2006, the Counter-Terrorism Act 2008, the Proceeds of Crime Act 2002 (as amended) and the Money Laundering, Terrorist Financing and Transfer of Funds (Information on the Payer) Regulations 2017);

24.      if in the United Kingdom, (a) it is a person having professional experience in matters relating to investments who falls within the definition of "investment professionals" in Article 19(5) of the FPO, or (b) it is a person who falls within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations etc.") of the FPO and (c) it is a UK Qualified Investor and (d) it is a person to whom this Announcement may otherwise lawfully be communicated;

25.      if it is within a Relevant State, it is an EU Qualified Investor;

26.      its participation in the Placing would not give rise to an offer being required to be made by it or any person with whom it is acting in concert pursuant to Rule 9 of the City Code on Takeovers and Mergers;

27.      it (and any person acting on its behalf) has the funds to pay for the Placing Shares for which it has agreed to subscribe and it will pay for the Placing Shares acquired by it in accordance with this Announcement and with any trade confirmation sent by the relevant Placing Agent (or on its behalf) to it in respect of its allocation of Placing Shares and its participation in the Placing on the due time and date set out herein against delivery of such Placing Shares to it, failing which the relevant Placing Shares may be placed with other Placees or sold as the relevant Placing Agent may, in its absolute discretion, determine and it will remain liable for any shortfall below the net proceeds of such sale and the placing proceeds of such Placing Shares and may be required to bear any stamp duty or stamp duty reserve tax (together with any interest or penalties due pursuant to the terms set out or referred to in this Announcement) which may arise upon the sale of such Placee's Placing Shares on its behalf;

28.      none of the Placing Agents, nor any Placing Agent Affiliate nor any person acting on their behalf is making any recommendations to it or advising it regarding the suitability or merits of any transaction it may enter into in connection with the Placing, and acknowledges that none of the Placing Agents, nor any Placing Agent Affiliate nor any person acting on their behalf has any duties or responsibilities to it for providing advice in relation to the Placing or in respect of any representations, warranties, undertakings or indemnities contained in the Placing Agreement or for the exercise or performance of any of the Placing Agents' rights and obligations thereunder, including any right to waive or vary any condition or exercise any termination right contained therein;

29.      (i) the person whom it specifies for registration as holder of the Placing Shares will be (a) the Placee or (b) the Placee's nominee, as the case may be, (ii) neither the Placing Agents nor the Company will be responsible for any liability to stamp duty or stamp duty reserve tax resulting from a failure to observe this requirement and (iii) the Placee and any person acting on its behalf agrees to acquire the Placing Shares on the basis that the Placing Shares will be allotted to the CREST stock account of the relevant Placing Agent which will hold them as settlement agent as nominee for the Placee until settlement in accordance with its standing settlement instructions with payment for the Placing Shares being made simultaneously upon receipt of the Placing Shares in the Placee's stock account on a delivery versus payment basis;

30.      any agreements entered into by it pursuant to these terms and conditions, and any non-contractual obligations arising out of or in connection with such agreements, shall be governed by and construed in accordance with the laws of England and Wales and it submits (on behalf of itself and on behalf of any person on whose behalf it is acting) to the exclusive jurisdiction of the courts of England and Wales as regards any claim, dispute or matter arising out of any such contract;

31.      it irrevocably appoints any director or duly authorised officer of any of the Placing Agents as its agent for the purposes of executing and delivering to the Company and/or its registrars any documents on its behalf necessary to enable it to be registered as the holder of any of the Placing Shares agreed to be taken up by it under the Placing;

32.      it is not a resident of any Restricted Jurisdiction and acknowledges that the Placing Shares have not been and will not be registered nor will a prospectus be cleared in respect of the Placing Shares under the securities legislation of any Restricted Jurisdiction and, subject to certain exceptions, may not be offered, sold, taken up, renounced, delivered or transferred, directly or indirectly, within any Restricted Jurisdiction;

33.      any person who confirms to a Placing Agent on behalf of a Placee an agreement to subscribe for Placing Shares and/or who authorises a Placing Agent to notify the Placee's name to the Company's registrar, has authority to do so on behalf of the Placee;

34.      the agreement to settle each Placee's acquisition of Placing Shares (and/or the acquisition of a person for whom it is contracting as agent) free of stamp duty and stamp duty reserve tax depends on the settlement relating only to an acquisition by it and/or such person direct from the Company of the Placing Shares in question. Such agreement assumes that the Placing Shares are not being acquired in connection with arrangements to issue depositary receipts or to issue or transfer the Placing Shares into a clearance service. If there were any such arrangements, or the settlement related to other dealing in the Placing Shares, stamp duty or stamp duty reserve tax may be payable, for which neither the Company nor the Placing Agents will be responsible. If this is the case, the Placee should take its own advice and notify the relevant Placing Agent accordingly;

35.      the allocation, allotment, issue and delivery to it, or the person specified by it for registration as holder, of Placing Shares will not give rise to a stamp duty or stamp duty reserve tax liability under (or at a rate determined under) any of sections 67, 70, 93 or 96 of the Finance Act 1986 (depository receipts and clearance services) and that it is not participating in the Placing as nominee or agent for any person or persons to whom the allocation, allotment, issue or delivery of Placing Shares would give rise to such a liability;

36.      when a Placee or any person acting on behalf of the Placee is dealing with a Placing Agent, any money held in an account with such Placing Agent on behalf of the Placee and/or any person acting on behalf of the Placee will not be treated as client money within the meaning of the relevant rules and regulations of the FCA. The Placee acknowledges that the money will not be subject to the protections conferred by the client money rules; as a consequence, this money will not be segregated in accordance with the client money rules and will be used by the relevant Placing Agent in the course of its business; and the Placee will rank only as a general creditor of the relevant Placing Agent (as the case may be);

37.      in order to ensure compliance with the Criminal Justice Act 1988, the Terrorism Act 2000, the Anti-Terrorism, Crime and Security Act 2001, the Proceeds of Crime Act 2002 (as amended) the Terrorism Act 2006, the Counter-Terrorism Act 2008 and the Money Laundering, Terrorist Financing and Transfer of Funds (Information on the Payer) Regulations 2017, and, to the extent applicable, any related or similar rules, regulations of any body having jurisdiction in respect thereof and the Money Laundering Sourcebook of the FCA, each Placing Agent (for itself and as agent on behalf of the Company) or the Company's registrars may, in their absolute discretion, require verification of its identity. Pending the provision to the relevant Placing Agent or the Company's registrars, as applicable, of evidence of identity, definitive certificates in respect of the Placing Shares may be retained at the relevant Placing Agent's absolute discretion or, where appropriate, delivery of the Placing Shares to it in uncertificated form may be delayed at the relevant Placing Agent's or the Company's registrars', as the case may be, absolute discretion. If within a reasonable time after a request for verification of identity a Placing Agent (for itself and as agent on behalf of the Company) or the Company's registrars have not received evidence satisfactory to them, the relevant Placing Agent and/or the Company may, at its absolute discretion, terminate its commitment in respect of the Placing, in which event the monies payable on acceptance of allotment will, if already paid, be returned without interest to the account of the drawee's bank from which they were originally debited;

38.      the Company, the Placing Agents, and others will rely upon the truth and accuracy of the foregoing representations, warranties, agreements, undertakings and acknowledgements;

39.      the basis of allocation will be determined by the Placing Agents and the Company at their absolute discretion and that the right is reserved to reject in whole or in part and/or scale back any participation in the Placing;

40.      its allocation (if any) of Placing Shares will represent a maximum number of Placing Shares which it will be entitled, and required, to subscribe for, and that the Company may call upon it to subscribe for a lower number of Placing Shares (if any), but in no event in aggregate more than the aforementioned maximum;

41.      irrevocably authorises the Company and the Placing Agents to produce this Announcement pursuant to, in connection with, or as may be required by any applicable law or regulation, administrative or legal proceeding or official inquiry with respect to the matters set forth herein;

42.      its commitment to subscribe for Placing Shares on the terms set out herein will continue notwithstanding any amendment that may in future be made to the terms of the Placing and that Placees will have no right to be consulted or require that their consent be obtained with respect to the Company's conduct of the Placing;

43.      time is of the essence as regards its obligations under this Appendix; 

44.      any document that is to be sent to it in connection with the Placing will be sent at its risk and may be sent to it at any address provided by it to a Placing Agent;

45.      it will be bound by the terms of the Articles;

46.      these terms and conditions in this Appendix and all documents into which this Appendix is incorporated by reference or otherwise validly forms a part and/or any agreements entered into pursuant to these terms and conditions and all agreements to acquire shares pursuant to the Placing will be governed by and construed in accordance with the laws of England and Wales and it submits to the exclusive jurisdiction of the courts of England and Wales in relation to any claim, dispute or matter arising out of any such contract, except that enforcement proceedings in respect of the obligation to make payment for the Placing Shares (together with any interest chargeable thereon) may be taken by the Company or the Placing Agents in any jurisdiction in which the relevant Placee is incorporated or in which any of its securities have a quotation on a recognised stock exchange;

47.      it is acting as principal only in respect of the Placing or, if it is acquiring the Placing Shares as a fiduciary or agent for one or more investor accounts, it is duly authorised to do so and it has full power and authority to make, and does make, the foregoing representations, warranties, acknowledgements, agreements and undertakings on behalf of each such accounts;

48.      its obligations are irrevocable and legally binding and shall not be capable of rescission or termination by it in any circumstances;

49.      subject to paragraph 50, none of the monies invested in the Placing by it is State Aid;

For the purposes of these terms and conditions:

"State Aid" means any aid, investment, grant or loan which was received by the recipient pursuant to a measure approved by the European Commission as compatible with Article 107 of the Treaty on the Functioning of the European Union in accordance with the principles laid down in the European Commission's Guidelines on State aid to promote risk finance investments (as those guidelines may be amended or replaced from time to time); and

50.      if it cannot give the warranty in paragraph 49, it is a condition of its participation in the Placing that it provides written confirmation to the Placing Agents as to the amount of money being invested in the Placing by it which will be State Aid.

The acknowledgements, agreements, undertakings, representations and warranties referred to above are given to each of the Company and the Placing Agents (for their own benefit and, where relevant, the benefit of any Placing Agent Affiliate or GENinCode Affiliate and any person acting on their behalf) and are irrevocable.

No claim shall be made against the Company, the Placing Agents, any Placing Agent Affiliate, any GENinCode Affiliate, or any other person acting on behalf of any of such persons by a Placee to recover any damage, cost, loss, charge or expense which it may suffer or incur by reason of or arising from or in connection with the performance of its obligations hereunder or otherwise howsoever in connection with the Placing or Admission.

No UK stamp duty or stamp duty reserve tax should be payable to the extent that the Placing Shares are issued or transferred (as the case may be) into CREST to, or to the nominee of, a Placee who holds those shares beneficially (and not as agent or nominee for any other person) within the CREST system and registered in the name of such Placee or such Placee's nominee.

Any arrangements to issue or transfer the Placing Shares into a depositary receipts system or a clearance service or to hold the Placing Shares as agent or nominee of a person to whom a depositary receipt may be issued or who will hold the Placing Shares in a clearance service, or any arrangements subsequently to transfer the Placing Shares, may give rise to stamp duty and/or stamp duty reserve tax, for which neither the Company nor the Placing Agents will be responsible and the Placee to whom (or on behalf of whom, or in respect of the person for whom it is participating in the Placing as an agent or nominee) the allocation, allotment, issue or delivery of Placing Shares has given rise to such stamp duty or stamp duty reserve tax undertakes to pay such stamp duty or stamp duty reserve tax forthwith and to indemnify on an after-tax basis and to hold harmless the Company and the Placing Agents in the event that any of the Company or any GENinCode Affiliate or the Placing Agents  or any Placing Agent Affiliate has incurred any such liability to stamp duty or stamp duty reserve tax.

In addition, Placees should note that they will be liable for any capital duty, stamp duty and all other stamp, issue, securities, transfer, registration, documentary or other duties or taxes (including any interest, fines or penalties relating thereto) payable outside the UK by them or any other person on the acquisition by them of any Placing Shares or the agreement by them to acquire any Placing Shares.

All times and dates in this Announcement may be subject to amendment. The Placing Agents shall notify the Placees and any person acting on behalf of the Placees of any such changes.

This Announcement has been issued by the Company and is the sole responsibility of the Company.

Each Placee, and any person acting on behalf of the Placee, acknowledges that the Placing Agents do not owe any fiduciary or other duties to any Placee in respect of any representations, warranties, undertakings or indemnities in the Placing Agreement.

The Placing Agents, which are authorised and regulated in the United Kingdom by the FCA, are acting for the Company and for no one else in connection with the Placing and will not regard any other person (whether or not a recipient of this Announcement) as a client in relation to the Placing or Admission and will not be responsible to anyone other than the Company for providing the protections afforded to clients of the Placing Agents or for affording advice in relation to the Placing or Admission, or any other matters referred to herein.

Each Placee and any person acting on behalf of a Placee acknowledges and agrees that the Placing Agents or any Placing Agent Affiliate may, at their absolute discretion, agree to become a Placee in respect of some or all of the Placing Shares.

The rights and remedies of the Placing Agents and the Company under these terms and conditions are in addition to any rights and remedies which would otherwise be available to each of them and the exercise or partial exercise of one will not prevent the exercise of others.

Each Placee may be asked to disclose in writing or orally to the Placing Agents and, if so, undertakes to provide:

1.         if he is an individual, his nationality; 

2.         if he is a discretionary fund manager, the jurisdiction in which the funds are managed or owned; and

3.         such other "know your client" information as a Placing Agent may reasonably request.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.